Drug intelligence / Profile preview

EB070

Development stage: Phase 1
Lead developer: Biotech Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

EB070 is an investigational monoclonal antibody designed to target thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine that initiates the inflammatory cascade in asthma. Developed by Biotech Pharmaceutical Co., Ltd., EB070 functions by neutralizing TSLP, thereby preventing the activation of downstream inflammatory pathways associated with both T2-high and T2-low asthma phenotypes. It is currently being evaluated in Phase I clinical trials to determine its safety, tolerability, and pharmacokinetic profile following subcutaneous administration in healthy adult volunteers.

Other names: Anti-TSLP Monoclonal Antibody

Targets

TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on EB070.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB070.

Explore the full profile